Plain-English translation of NCT07135102 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called [225Ac]Ac-PSMA-XT for men with metastatic castration-resistant prostate cancer—a type of advanced cancer that has spread to other parts of the body and no longer responds to standard hormone therapies. The medication is a radioactive injection that is designed to find and attack prostate cancer cells. Researchers are studying whether this treatment is safe and whether it helps shrink tumors.
Men with advanced prostate cancer that has stopped responding to standard treatments have very limited options. This medication is designed to target cancer cells more precisely using radioactivity, offering a potentially new way to help patients whose cancers are no longer responding to conventional therapies.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the experimental medication, likely on an outpatient basis. The study team would monitor you closely with blood tests, imaging scans, and physical exams to watch for side effects and to see whether the treatment is working. The exact schedule of visits and length of the study would be explained to you during the consent process, but as a Phase 1 trial, the focus is on learning whether the treatment is safe before determining how well it works.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China